Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06367803
Status:
COMPLETED
Last Update Posted:
2024-04-16
First Post:
2024-04-11
Brief Title:
Cost Analysis of Vascular Surgical Techniques
Sponsor:
University Hospital of Limerick
Organization:
University Hospital of Limerick
Study Overview
Official Title:
Cost Analysis of Vascular Surgical Techniques Comparing Limb Revascularisation and Amputation in Patients With CLTI at University Hospital Limerick
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Whilst mortality rates and surgical limitations are widely known and understood for each intervention performed the cost implications in UHL are not known Therefore it is deemed a matter of interest to understand these costs and weigh them against the mortality rates for each intervention if available
Detailed Description:
Surgical interventions for patients with CLTI include endovascular revascularisation by-pass revascularisation and amputation
Clinical outcomes vary greatly for each intervention The 5-year mortality rate for major amputations ie below knee BKA and above knee AKA is reported to range from 30 to 70 with AKA having the higher rate of mortality Concomitant Type II diabetes increases these rates of mortality for both AKA and BKA
Whilst mortality rates are widely known and understood for each intervention performed the cost implications in UHL are not known Therefore it is deemed a matter of interest to understand these costs and weigh them against the mortality rates for each intervention
Clinical outcomes vary greatly for each intervention The 5-year mortality rate for major amputations ie below knee BKA and above knee AKA is reported to range from 30 to 70 with AKA having the higher rate of mortality Concomitant Type II diabetes increases these rates of mortality for both AKA and BKA
Whilst mortality rates are widely known and understood for each intervention performed the cost implications in UHL are not known Therefore it is deemed a matter of interest to understand these costs and weigh them against the mortality rates for each intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None